7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.
Human subjects and rhesus monkeys receiving the antitumor agent methotrexate at the high dose levels recently introduced into clinical use (greater than 50 mg/kg) excrete significant amounts of the metabolite 7-hydroxymethotrexate. The metabolite is not detected in these species after methotrexate therapy at conventional dose levels. The evidence indicates that in primates, the in vivo conversion of methotrexate to 7-hydroxymethotrexate is a dose-dependent phenomenon, with the enzyme system(s) catalyzing the reaction having a low affinity for the drug.
D000328:Adult; D000818:Animals; D001859:Bone Neoplasms / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002648:Child; D005260:Female; D006651:Histocytochemistry; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy; D008253:Macaca mulatta; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use / Q000652:urine; D008875:Middle Aged; D012516:Osteosarcoma / Q000188:drug therapy; D013997:Time Factors
C011864:7-hydroxymethotrexate; D008727:Methotrexate